secwatch.observer — SEC 8-K summary
======================================

Issuer:     ASSEMBLY BIOSCIENCES, INC. (ASMB)
CIK:        0001426800
Form:       8-K
Filed at:   2026-03-19T23:59:59+00:00
Accession:  0001193125-26-115980
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Assembly Biosciences reports 2025 revenue of $72.3M; net loss narrows; licenses HPI program to Gilead
--------------------------------------------------------------------------------

- Revenue from Gilead collaboration was $72.3M in 2025 (vs $28.5M in 2024); net loss per share $0.55 (vs $6.69).
- Cash and marketable securities $248.1M as of Dec 31, 2025, projected to fund operations into 2028.
- Licensed helicase-primase inhibitor program (ABI-5366, ABI-1179) to Gilead; received net $35M option fee.
- Gilead declined option on ABI-4334 (HBV capsid modulator); Assembly seeking partner for that program.
- Phase 2 initiation for ABI-6250 (HDV entry inhibitor) anticipated by end of 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1426800/000119312526115980/0001193125-26-115980-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1426800/000119312526115980/asmb-20260319.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-115980

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer